Long-term observational study of the safety of Roflumilast

Trial Identifier:	D7120R00003
Sponsor:	AstraZeneca
NCTID::	NCT03381573
Start Date:	March 2017
Primary Completion Date:	September 2022
Study Completion Date:	September 2022
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Germany	Bremen, Germany
Norway	Oslo, Norway, 0483
Sweden	Solna, Sweden
USA, Massachusetts	Cambridge, Massachusetts, USA, 02139

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.